Validation of RiskCheck Bladder Cancer©, Version 5.0 for Risk-Adapted Screening of Bladder Cancer

被引:1
|
作者
Martini, T. [1 ]
Mayr, R. [1 ]
Lodde, M. [1 ]
Seitz, C. [5 ]
Trenti, E. [1 ]
Comploj, E. [1 ]
Palermo, S. [1 ]
Pycha, A. [1 ]
Mian, C. [2 ]
Zywica, M. [3 ]
Weidner, W. [4 ]
Luedecke, G. [4 ]
机构
[1] Gen Hosp Bolzano, Dept Urol, IT-39100 Bolzano, Italy
[2] Gen Hosp Bolzano, Dept Pathol, IT-39100 Bolzano, Italy
[3] Hosp Bressanone, Dept Vasc Surg, Bressanone, Italy
[4] Univ Giessen, Dept Urol Pediat Urol & Androl, Univ Clin Giessen & Marburg GmbH, D-35390 Giessen, Germany
[5] Med Univ Vienna, Dept Urol, Vienna, Austria
关键词
Bladder cancer; Risk-adapted screening; RiskCheck Bladder Cancer (c); Version; 5.0; Risk factors; PROSTATE-CANCER; FOLLOW-UP; MORTALITY; WORKERS; COHORT; POPULATION; GUIDELINES; CARCINOMA; RADIATION; EXPOSURE;
D O I
10.1159/000351036
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The aim of the study was to assess the strength of the online tool RiskCheck Bladder Cancer (c), version 5.0 (RCBC) for early detection of bladder cancer (BC). Materials and Methods: RCBC was evaluated retrospectively based on the data of 241 patients, of which 141 were suffering from BC. Statistical analysis was performed by descriptive statistics, nonparametric group comparison, classification tree analysis and ROC analysis. Results: ROC analysis of the risk classification showed a sensitivity of 71.6%, a specificity of 56.5%, a positive predictive value of 67.8%, a negative predictive value of 52% and an accuracy of 63.5%. BC risk factors ranked by importance are time of smoking (p < 0.0001), gender (within the nonsmoking group: p < 0.009), occupational toxin exposure (within the group <35 years of smoking: p < 0.048) and amount of consumed cigarettes resulting in a 95% association with BC (within the group >35 years of smoking: p < 0.0001). Conclusions:The high predictive power of RCBC for the identification of asymptomatic patients living under risk could be demonstrated. (c) 2013 S. Karger AG, Basel
引用
收藏
页码:175 / 181
页数:7
相关论文
共 50 条
  • [31] SCREENING FOR BLADDER CANCER
    PARKES, HG
    PROCEEDINGS OF THE ROYAL SOCIETY OF MEDICINE-LONDON, 1971, 64 (12): : 1207 - &
  • [32] A Case for Risk-adapted Management of Low-grade Bladder Tumors
    Soloway, Mark
    Matulay, Justin T.
    Kamat, Ashish M.
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (01): : 128 - 129
  • [33] Risk-adapted screening is best
    Svoboda, Elizabeth
    NATURE, 2020, 579 (7800) : S21 - S21
  • [34] Development and evaluation of a risk prediction tool for risk-adapted screening of colorectal cancer in China
    Hang, Dong
    Sun, Dianjianyi
    Du, Lingbin
    Huang, Jianv
    Li, Jiacong
    Zhu, Chen
    Wang, Le
    He, Jingjing
    Zhu, Xia
    Zhu, Meng
    Song, Ci
    Dai, Juncheng
    Yu, Canqing
    Xu, Zekuan
    Li, Ni
    Ma, Hongxia
    Jin, Guangfu
    Yang, Ling
    Chen, Yiping
    Du, Huaidong
    Cheng, Xiangdong
    Chen, Zhengming
    Lv, Jun
    Hu, Zhibin
    Li, Liming
    Shen, Hongbing
    CANCER LETTERS, 2024, 597
  • [35] A phase II trial of risk-adapted treatment for muscle invasive bladder cancer after neoadjuvant accelerated MVAC.
    Geynisman, Daniel M.
    Abbosh, Philip
    Zibelman, Matthew R.
    Feldman, Rebecca
    McConkey, David James
    Hahn, Noah M.
    Bivalacqua, Trinity
    Trabulsi, Edouard John
    Lallas, Costas D.
    Hoffman-Censits, Jean H.
    Viterbo, Rosalia
    Horwitz, Eric M.
    Churilla, Thomas M.
    Alpaugh, R. Katherine
    Greenberg, Richard E.
    Smaldone, Marc C.
    Uzzo, Robert
    Chen, David
    Kutikov, Alexander
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [36] Determining the Appropriate Risk-Adapted Screening Age for Familial Breast Cancer Reply
    Fallah, Mahdi
    Mukama, Trasias
    Kharazmi, Elham
    JAMA ONCOLOGY, 2020, 6 (06) : 934 - 935
  • [37] Risk-adapted moderate hypofractionation of prostate cancer
    Schoerghofer, Andreas
    Groher, Michael
    Karner, Josef
    Kopp, Andrea
    Kametriser, Gerhard
    Kunit, Thomas
    Holzinger, Josef
    Sedlmayer, Felix
    Wolf, Frank
    STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (10) : 894 - 901
  • [38] Risk-adapted adjuvant treatment of colon cancer
    Reinacher-Schick, A.
    GASTROENTEROLOGE, 2012, 7 (01): : 14 - 23
  • [39] Validation of the Japanese version of the Body Image Scale for bladder cancer patients
    Miho Sato
    Takahiro Osawa
    Takashige Abe
    Michitaka Honda
    Madoka Higuchi
    Shuhei Yamada
    Jun Furumido
    Hiroshi Kikuchi
    Ryuji Matsumoto
    Yasuyuki Sato
    Yoshihiro Sasaki
    Toru Harabayashi
    Satoru Maruyama
    Norikata Takada
    Keita Minami
    Hiroshi Tanaka
    Ken Morita
    Akira Kashiwagi
    Sachiyo Murai
    Yoichi M. Ito
    Katsuhiko Ogasawara
    Nobuo Shinohara
    Scientific Reports, 12
  • [40] Validation of the Japanese version of the Body Image Scale for bladder cancer patients
    Sato, Miho
    Osawa, Takahiro
    Abe, Takashige
    Honda, Michitaka
    Higuchi, Madoka
    Yamada, Shuhei
    Furumido, Jun
    Kikuchi, Hiroshi
    Matsumoto, Ryuji
    Sato, Yasuyuki
    Sasaki, Yoshihiro
    Harabayashi, Toru
    Maruyama, Satoru
    Takada, Norikata
    Minami, Keita
    Tanaka, Hiroshi
    Morita, Ken
    Kashiwagi, Akira
    Murai, Sachiyo
    Ito, Yoichi M.
    Ogasawara, Katsuhiko
    Shinohara, Nobuo
    SCIENTIFIC REPORTS, 2022, 12 (01)